ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

10 дек 2022 10:00:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05 дек 2022 07:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

01 дек 2022 07:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

21 ноя 2022 16:05:00 Источник Nasdaq GlobeNewswire

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

21 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

03 ноя 2022 16:05:01 Источник Nasdaq GlobeNewswire

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers 

11 окт 2022 08:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

05 окт 2022 16:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

12 сен 2022 08:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

02 сен 2022 08:00:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

03 авг 2022 16:05:01 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

28 июл 2022 07:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

08 июл 2022 16:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

15 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology

02 июн 2022 16:10:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

26 май 2022 08:00:01 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

04 май 2022 16:05:03 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

02 май 2022 16:05:01 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

05 апр 2022 16:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

09 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire